Vantis Vascular

Executive Summary

Vantis Vascular is a private medical device company based in San Jose, California, focused on developing minimally invasive solutions for complex coronary and peripheral vascular interventions. Founded in 2015, the company's lead product, the CrossFast™ Advanced Vascular Delivery System, aims to enhance deliverability and control during percutaneous coronary interventions (PCI). The system addresses a critical need in interventional cardiology by improving navigation through challenging anatomy, potentially reducing procedure time and improving patient outcomes. Vantis Vascular operates in the competitive cardiovascular device market, targeting an unmet need for better delivery systems in complex cases. While the company is early-stage with no publicly disclosed funding or valuation, its focused product pipeline and experienced team (implied by its 10-year history) position it for potential growth pending regulatory clearance. The company's success hinges on obtaining FDA 510(k) clearance and subsequent commercial adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for CrossFast Delivery System70% success
• Q4 2026Clinical Study Initiation for Expanded Indications60% success
• TBDStrategic Partnership with Major Cardiovascular Device Distributor50% success